MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corporation

In a report released yesterday, Brandon Folkes from H.C. Wainwright maintained a Buy rating on MannKind, with a price target of $10.00. The company...

H.C. Wainwright Keeps Their Buy Rating on MannKind (MNKD)

Leerink Partners analyst reiterated a Buy rating on MannKind today and set a price target of $4.16. MannKind has an analyst consensus of Strong Buy...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MNKD	$3.74	+11.98%	4.97M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MNKD	$3.74	+12.0%	4.97M
3
4
5
6

MNKD

Get MannKind Corporation Data in Excel

Get MannKind Corporation Data in Excel